Skip to main content
Clinical Trials/NL-OMON38389
NL-OMON38389CompletedNot Applicable

The RVCL-MRI study: neuroimaging findings and cerebrovascular reactivity in preclinical and clinical disease stages of Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL), in migraine patients and healthy controls. - RVCL-MRI study

eids Universitair Medisch Centrum0 sites90 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
90

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • Patient group (RVCL and migraine):
  • - age >=18 years
  • - Diagnosed with :
  • i) RVCL with proven TREX1 mutation; AND/OR
  • ii) migraine with or without aura according to the criteria of the International Headache Society (IHS)
  • - ability and willingness to provide written informed consent;control subjects:
  • -age >=18 years
  • - Not genetically related to an RVCL patient OR genetic testing has ruled out TREX1 mutations
  • - no (history) of migraine attacks
  • - age and sex matched with the patients
  • - Ability and willingness to provide written informed consent

Exclusion Criteria

  • All subjects:
  • - Subjects who do not want to be informed about unexpected findings that are considered serious, with prognostic or therapeutic consequences. This does not concern genetic test results.
  • - History of severe kidney dysfunction
  • - Previous allergic-like reaction to gadolinium-containing contrast agents
  • - Contraindications to MR Imaging (such as presence of metal objects in/on the body that cannot be removed);Migraine patients and control subjects:
  • - Presence of known (cerebro) vascular diseases such as overt manifestations of hypertensive/ atherosclerotic vascular disease, excessive anticoagulation (INR >3.0), CNS disorders, vasculitis, blood dyscrasia, diabetes mellitus, severe clinical relevant carotid artery stenosis. ;Specific exclusion criteria for participants in the cerebrovascular reactivity measurements:
  • - Severe asthma
  • - Seizures within the previous year

Investigators

Similar Trials